Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: A randomised, prospective trial

Acta Ophthalmologica

Volumn 93, Issue 2, 2015, Pages e154-e159

  Zehetner, Claus ^a   Kralinger, Martina T ^a   Modi, Yasha S ^b   Waltl, Inga ^a   Ulmer, Hanno ^a   Kirchmair, Rudolf ^c   Bechrakis, Nikolaos E ^a   Kieselbach, Gerhard F ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Aflibercept; age related macular degeneration; ranibizumab; vascular endothelial growth factor (VEGF)

Indexed keywords

AFLIBERCEPT; POVIDONE IODINE; RANIBIZUMAB; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

ADULT; AGE DISTRIBUTION; AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; BLOOD SAMPLING; CHORIORETINOPATHY; CLINICAL ARTICLE; COHORT ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; MALE; PRIORITY JOURNAL; PSEUDOPHAKIA; RANDOMIZED CONTROLLED TRIAL; SEX RATIO; TREATMENT DURATION; TREATMENT FAILURE; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; BLOOD; COMPARATIVE STUDY; INTRAVITREAL DRUG ADMINISTRATION; OPTICAL COHERENCE TOMOGRAPHY; PHYSIOLOGY; PROSPECTIVE STUDY; VISUAL ACUITY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MALE; PROSPECTIVE STUDIES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84923222140     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/aos.12604     Document Type: Article

References (29)

1. Avery RL, (2014): What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned? Br J Ophthalmol 98 (Suppl 1): i7-i10.
2. Avery RL, Castellarin AA, Steinle NC, et al. (2014): Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol [Epub ahead of print].
3. Carneiro AM, Costa R, Falcao MS, et al. (2012): Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmol 90: e25-e30.
4. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, &, Reeves BC, (2012): Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 119: 1399-1411.
5. Ferrara N, Damico L, Shams N, Lowman H, &, Kim R, (2006): Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina (Philadelphia, PA) 26: 859-870.
6. Heiduschka P, Fietz H, Hofmeister S, et al. (2007): Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 48: 2814-2823.
7. Holash J, Davis S, Papadopoulos N, et al. (2002): VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 99: 11393-11398.
8. Kim H, Robinson SB, &, Csaky KG, (2009): FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye. Mol Vis 15: 2803-2812.
9. Klaver CC, Wolfs RC, Vingerling JR, Hofman A, &, de Jong PT, (1998): Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. Arch Ophthalmol 116: 653-658.
10. Klein R, Cruickshanks KJ, Myers CE, et al. (2013): The relationship of atherosclerosis to the 10-year cumulative incidence of age-related macular degeneration: the Beaver Dam studies. Ophthalmology 120: 1012-1019.
11. Krohne TU, Holz FG, &, Meyer CH, (2014): [Pharmacokinetics of intravitreally administered VEGF inhibitors]. Ophthalmologe 111: 113-120.
12. Kubicka-Trzaska A, Wilanska J, Romanowska-Dixon B, &, Sanak M, (2014): Circulating anti-retinal antibodies in response to anti-angiogenic therapy in exudative age-related macular degeneration. Acta Ophthalmol [Epub ahead of print].
13. Lu JF, Bruno R, Eppler S, Novotny W, Lum B, &, Gaudreault J, (2008): Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 62: 779-786.
14. Martin DF, Maguire MG, Fine SL, et al. (2012): Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119: 1388-1398.
15. Matsuyama K, Ogata N, Matsuoka M, Wada M, Takahashi K, &, Nishimura T, (2010): Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. Br J Ophthalmol 94: 1215-1218.
16. Papadopoulos N, Martin J, Ruan Q, et al. (2012): Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15: 171-185.
17. Powner MB, McKenzie JA, Christianson GJ, Roopenian DC, &, Fruttiger M, (2014): Expression of neonatal Fc receptor in the eye. Invest Ophthalmol Vis Sci 55: 1607-1615.
18. Proetzel G, &, Roopenian DC, (2014): Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies. Methods 65: 148-153.
19. Renard C, Grene-Lerouge N, Beau N, Baud F, &, Scherrmann JM, (1997): Pharmacokinetics of digoxin-specific Fab: effects of decreased renal function and age. Br J Clin Pharmacol 44: 135-138.
20. Roopenian DC, &, Akilesh S, (2007): FcRn: the neonatal Fc receptor comes of age. Nature reviews. Immunology 7: 715-725.
21. Rudge JS, Holash J, Hylton D, et al. (2007): VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci USA 104: 18363-18370.
22. Sugita S, (2009): Role of ocular pigment epithelial cells in immune privilege. Arch Immunol Ther Exp 57: 263-268.
23. Tsurumi Y, Murohara T, Krasinski K, Chen D, Witzenbichler B, Kearney M, Couffinhal T, &, Isner JM, (1997): Reciprocal relation between VEGF and NO in the regulation of endothelial integrity. Nat Med 3: 879-886.
24. Vingerling JR, Dielemans I, Bots ML, Hofman A, Grobbee DE, &, de Jong PT, (1995): Age-related macular degeneration is associated with atherosclerosis. The Rotterdam Study. Am J Epidemiol 142: 404-409.
25. Wang X, Sawada T, Sawada O, Saishin Y, Liu P, &, Ohji M, (2014): Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration. Am J Ophthalmol 158: 738-744 e173.
26. Xu L, Lu T, Tuomi L, et al. (2013): Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach. Invest Ophthalmol Vis Sci 54: 1616-1624.
27. Zachary I, Mathur A, Yla-Herttuala S, &, Martin J, (2000): Vascular protection: a novel nonangiogenic cardiovascular role for vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 20: 1512-1520.
28. Zehetner C, Kirchmair R, Huber S, Kralinger MT, &, Kieselbach GF, (2013): Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. Br J Ophthalmol 97: 454-459.
29. Zhang J, Silva T, Yarovinsky T, et al. (2010): VEGF blockade inhibits lymphocyte recruitment and ameliorates immune-mediated vascular remodeling. Circ Res 107: 408-417.